CN105901736A - 含有青梅提取物的组合物在制备降尿酸保健品中的用途 - Google Patents
含有青梅提取物的组合物在制备降尿酸保健品中的用途 Download PDFInfo
- Publication number
- CN105901736A CN105901736A CN201610395708.0A CN201610395708A CN105901736A CN 105901736 A CN105901736 A CN 105901736A CN 201610395708 A CN201610395708 A CN 201610395708A CN 105901736 A CN105901736 A CN 105901736A
- Authority
- CN
- China
- Prior art keywords
- parts
- plum extract
- extract
- uric acid
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 60
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 54
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 229940116269 uric acid Drugs 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 230000003247 decreasing effect Effects 0.000 title abstract 2
- 241000319345 Metacordyceps liangshanensis Species 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 230000036541 health Effects 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 23
- 239000000047 product Substances 0.000 claims description 21
- 210000000582 semen Anatomy 0.000 claims description 21
- 239000009636 Huang Qi Substances 0.000 claims description 19
- 235000011158 Prunus mume Nutrition 0.000 claims description 19
- 244000018795 Prunus mume Species 0.000 claims description 19
- 239000002994 raw material Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000012153 distilled water Substances 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 11
- 238000005202 decontamination Methods 0.000 claims description 10
- 230000003588 decontaminative effect Effects 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- -1 reflux Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 238000003801 milling Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 2
- 210000004072 lung Anatomy 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 239000003053 toxin Substances 0.000 abstract description 2
- 231100000765 toxin Toxicity 0.000 abstract description 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 240000005717 Dioscorea alata Species 0.000 abstract 1
- 240000008620 Fagopyrum esculentum Species 0.000 abstract 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 241001571764 Lysimachia christinae Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 230000013872 defecation Effects 0.000 abstract 1
- 230000027939 micturition Effects 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 19
- 238000011282 treatment Methods 0.000 description 10
- 201000001431 Hyperuricemia Diseases 0.000 description 9
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 9
- 229960003459 allopurinol Drugs 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 201000005569 Gout Diseases 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 244000269722 Thea sinensis Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 235000013616 tea Nutrition 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- 208000013824 Acidemia Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 241000962514 Alosa chrysochloris Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000004153 Hibiscus sabdariffa Species 0.000 description 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于保健品领域,具体涉及含有青梅提取物的组合物在制备降尿酸保健品中的用途。该组合物由以下重量份数的原料制备而成:青梅提取物18‑30份、土茯苓10‑20份、白附子6‑16份、萆薢6‑12份、陈皮10‑18份、黄芪2‑8份、荞麦8‑16份、独活4‑10份、凉山虫草4‑10份、金钱草2‑8份和甘草4‑10份。本发明配伍科学合理、主次分明、相互增益,各组分协调相和,具有祛风除湿、解毒散结、补气固表、利尿托毒、补肺益肾和清热利便等功效。经试验发现,本发明提供的含有青梅提取物的保健品能有效地降低人体尿酸,具有毒性小、安全性高、针对性强的特点。
Description
技术领域
本发明属于保健品领域,具体涉及含有青梅提取物的组合物在制备降尿酸保健品中的用途。
背景技术
尿酸是人体内嘌呤代谢的最终产物。人体尿酸值处于一个动态的范围,一般情况下,男性体内的血尿酸值要远高于女性,男性尿酸值大约149unmol/L~416umol/L,女性尿酸值一般在89umol/L~257umol/L之间,如果体内积聚过多尿酸,造成代谢失调,就是尿酸过高。
尿酸值偏高原因分析:
首先,是排放尿酸受到阻碍:尿酸不能够及时排出体外,就会滞留在体内,引起体内尿酸量的增多,一般情况下是因为肾功能异常造成的;其次,是生成尿酸过多而造成排放不尽:尿酸生成过多导致正常的排放尿酸量不能及时将过多的尿酸排出体外,这类病人主要常见于经常性大量进食含有嘌呤成分丰富的食物,同时肥胖人群,高血压高血脂人群居多;最后,还可能由其他因素引起:如尿路感染、生活无规律,过度劳累等因素导致体内环境受到破坏,而引起的尿酸高值偏高的现象。
尿酸值偏高症状:
无症状高尿酸血症的危险性在于痛风发作,或最终发生肾结石。高尿酸血症病人发生痛风的可能性,大致和血清尿酸水平增高的程度成比例。据观察,在青春期开始有高尿酸血症的男性,至第一次痛风发作之间的间隔一般为20~25年或更长。这并不意味着要对所有高尿酸血症病人都给予预防性治疗,以防止其中少数人痛风发作。
一般认为,对无症状性高尿酸血症无须治疗。但持久的高血尿酸,有可能造成尿酸结晶和尿酸盐结晶在肾盂、输尿管或肾小管及肾间质沉积,造成肾损害,引起肾结石,所以应该寻找高血尿酸的原因,如利尿药、降压药、化疗药等药物因素及肾病、血液病、糖尿病等,同时应避免肥胖、高嘌呤及高热量饮食、酗酒、过度疲劳、精神紧张、创伤、湿冷等诱发因素。降低血尿酸,这是有益无害的事。当有下列几种情况时,则应考虑治疗:①有痛风临床症状;②有痛风家族史;③上述—些原因排除后,仍有高血尿酸(超过0.54毫摩尔/升,即超过9毫克/分升)。
如果长时间尿酸过高,就可能引起痛风。痛风是由于嘌呤代谢紊乱导致血尿酸增加而引起组织损伤的一组疾病,起因是长时间的尿酸过高引起的,尿酸在关节、肾处沉积等问题。病变常侵犯关节、肾脏等组织,发病年龄多在40以上,患病率随年龄而增加,男女之比为50:1,多数妇性病人为绝经后女妇,常在春、秋季节发病。常见的症状:1)无症状期:有高尿酸血症而无临床症状;2)痛风性关节炎;3)痛风结节,常见于耳轮和关节周围,呈大小不一的降起赘生物,可向皮肤破溃,排出白色的尿酸盐结晶;4)肾脏病变;5)少数有发热、头痛等全身症状。
目前,临床治疗高尿酸症的药物品种不多,在急性发病期主要应用秋水仙碱、非甾体类抗炎药和激素;缓解期主要应用促进尿酸排泄药、抑制尿酸合成药等。虽然西药治疗具有见效快、服用方便的优点,但是长期服用会对人体的肝、肾造成严重的损伤。这些药物在治疗中均存在缺陷,疗效差、副作用大、治疗不彻底成为其临床应用的瓶颈。
与西药治疗相比,中医具有丰富的用药经验和中医药理论基础,讲求辨证论治,无论是对病因病机的认识还是诊断治疗方面现代中医都取得了一定的进展,对于降低人体尿酸值具有更好的效果。
中国专利申请201210276339.5公开了一种降低尿酸的营养保健品,所述保健品每剂量含有效的保健治疗成分如下:小鲣鱼萃取物150-350mg、菠萝蛋白酶65-135mg、芹菜提取物25-85mg、洛神葵30-80mg、玉米丝30-75mg。该保健品富含酵素、乳酸脱氢酵素LDH,促进体内尿酸和乳酸的代谢。
中国专利申请201110444946.3公开了一种有助降低尿酸的保健茶,其配方为:绿茶30%、车前草20%、金钱草20%、菊花10%和葛根20%。该保健茶从利尿、排毒、清火和促进微循环角度降低人体尿酸含量和尿酸对人体的损害。但该保健茶组方简单,理论依据不充分;加工工艺粗糙,采用泡茶的方式饮用,其有效成分常常因为持续高温浸泡而受到破坏,或因浸泡时间太短不能被充分的提取,质量稳定性差、生物利用度不高。
发明内容
为了克服现有技术中降低人体尿酸含量保健品存在的不足,本发明的目的在于提供一种稳定性好、生物利用度高、毒副作用小、安全性高的含有青梅提取物的组合物及其在制备降尿酸保健品中的用途。
本发明提供了一种含有青梅提取物的组合物在制备降尿酸保健品中的用途,所述含有青梅提取物的组合物包括如下制备原料及其重量份数:
青梅提取物18-30份、土茯苓10-20份、白附子6-16份、萆薢6-12份、陈皮10-18份、黄芪2-8份、荞麦8-16份、独活4-10份、凉山虫草4-10份、金钱草2-8份和甘草4-10份。
进一步地,所述含有青梅提取物的组合物,包括如下制备原料及其重量份数:
青梅提取物24份、土茯苓15份、白附子11份、萆薢9份、陈皮14份、黄芪5份、荞麦12份、独活7份、凉山虫草7份、金钱草5份和甘草7份。
进一步地,所述含有青梅提取物的组合物,包括如下制备原料及其重量份数:
青梅提取物18份、土茯苓10份、白附子6份、萆薢6份、陈皮10份、黄芪2份、荞麦8份、独活4份、凉山虫草4份、金钱草2份和甘草4份。
进一步地,所述含有青梅提取物的组合物,包括如下制备原料及其重量份数:
青梅提取物30份、土茯苓20份、白附子16份、萆薢12份、陈皮18份、黄芪8份、荞麦16份、独活10份、凉山虫草10份、金钱草8份和甘草10份。
进一步地,所述含有青梅提取物的组合物被制成片剂、胶囊剂、口服液或冲剂。
进一步地,所述含有青梅提取物的组合物由以下步骤制得:
S1、采摘新鲜青梅,洗净后晾干,加入青梅重量1-2倍的蒸馏水,高速搅拌机研磨,过滤去杂质,得到青梅浆液;
S2、将S1制备的青梅浆液用70-80%的乙醇溶液回流提取1-3次,每次3-6h,合并提取液,静置,过滤去杂质,得青梅提取物,备用;
S3、称取其他各味原料,分别去杂质,洗净,烘干,切片后分别粉碎成粗粉;
S4、将土茯苓、萆薢、黄芪、独活和金钱草的粗粉混匀,按照上述粗粉总重量的6-12倍量加入体积浓度为70-95%的乙醇溶液,浸泡12-24h,回流提取2-4次,每次3-5h,过滤并保留滤渣,合并滤液,减压蒸馏除去乙醇,浓缩,得浓缩液,备用;
S5、将白附子、陈皮、荞麦、凉山虫草、甘草的粗粉与S3的滤渣混匀,按照上述粗粉及滤渣总重量的7-9倍量加入蒸馏水,回流提取3-6小时,过滤,合并滤液,浓缩,得浓缩液,备用;
S6、将S2所得的青梅提取物与S4、S5所得的浓缩液合并,充分混合,离心喷雾干燥,即得。
进一步地,所述步骤S1中高速搅拌机的研磨转速为500-1000rpm,研磨时间为10-25min。
进一步地,所述步骤S2中提取料液比为1:1-25。
进一步地,所述步骤S2中提取料液比为1:10。
进一步地,所述步骤S6中离心喷雾干燥机的进风温度为110-140℃,出风温度为75-95℃。
本发明中青梅收敛生精、敛肺止咳、增强代谢、涩肠止泻;土茯苓和白附子,祛风除湿、解毒散结、祛瘀止痛和通利关节;萆薢、陈皮和黄芪,补气固表、利尿托毒、排脓敛疮、下气消积;荞麦、独活、凉山虫草和金钱草,补肺益肾、开胃宽肠、清热利便、解毒消肿;甘草开胃和中,调和诸药。各组分协同促进,主次分明,相辅相成。动物试验说明,本发明能有效地降低大鼠体内的尿酸水平,具有毒性小,无副作用等特点。
与现有技术相比,本发明具有如下技术优势:
1、本发明保健品由青梅提取物及纯天然中草药组成,各组分协调相和,具有疗效好、标本兼治、侧重调理的优势。
2、本发明保健品中含有多种中药组分,且组分性温、平,驱邪不伤正,固散有道,开阖适度,作用靶点众多,能及时有效的降低人体尿酸和控制病情的发展。
3、本发明保健品制备工艺简便易行、无副作用,易于推广应用。
具体实施方式
本领域技术人员应理解,以下实施例中所公开的技术代表本发明人发现的在本发明的实践中发挥良好作用的技术。然而,在所公开的具体实施方案中可以做出许多改变,并仍然获得相同或相似的结果,而不脱离本发明的精神和范围。
实施例1:
本发明实施例1降尿酸保健品由以下重量份数的原料制备而成:青梅提取物24份、土茯苓15份、白附子11份、萆薢9份、陈皮14份、黄芪5份、荞麦12份、独活7份、凉山虫草7份、金钱草5份和甘草7份。
制备方法如下:
S1、采摘新鲜青梅,洗净后晾干,加入青梅重量1.5倍的蒸馏水,750rpm高速搅拌研磨20min,过滤去杂质,得到青梅浆液;
S2、将S1制备的青梅浆液用75%的乙醇溶液回流提取2次,每次3h,提取料液比为1:13,合并提取液,静置,过滤去杂质,得青梅提取物,备用;
S3、称取其他各味原料,分别去杂质,洗净,烘干,切片后分别粉碎成粗粉;
S4、将土茯苓、萆薢、黄芪、独活和金钱草的粗粉混匀,按照上述粗粉总重量的9倍量加入体积浓度为85%的乙醇溶液,浸泡18h,回流提取3次,每次4h,过滤,保留滤渣,合并滤液,减压蒸馏除去乙醇,浓缩,得浓缩液,备用;
S5、将白附子、陈皮、荞麦、凉山虫草、甘草的粗粉与S3的滤渣混匀,按照上述粗粉及滤渣总重量的8倍量加入蒸馏水,回流提取5小时,过滤,合并滤液,浓缩,得浓缩液,备用;
S6、将S2所得的青梅提取物与S4、S5所得的浓缩液合并,充分混合,以进风温度为125℃、出风温度为85℃进行离心喷雾干燥,制备成组合物;
S7、向S6所得的组合物中添加相应的辅料,利用现代通用制备技术,压片,制备成片剂。
实施例2:
本发明实施例2降尿酸保健品由以下重量份数的原料制备而成:青梅提取物18份、土茯苓10份、白附子6份、萆薢6份、陈皮10份、黄芪2份、荞麦8份、独活4份、凉山虫草4份、金钱草2份和甘草4份。
制备方法如下:
S1、采摘新鲜青梅,洗净后晾干,加入青梅等重量的蒸馏水,500rpm高速搅拌研磨10min,过滤去杂质,得到青梅浆液;
S2、将S1制备的青梅浆液用75%的乙醇溶液回流提取5h,提取料液比为1:10,合并提取液,静置,过滤去杂质,得青梅提取物,备用;
S3、称取其他各味原料,分别去杂质,洗净,烘干,切片后分别粉碎成粗粉;
S4、将土茯苓、萆薢、黄芪、独活和金钱草的粗粉混匀,按照上述粗粉总重量的6倍量加入体积浓度为70%的乙醇溶液,浸泡12h,再回流煎煮提取2次,每次3h,过滤,保留滤渣,合并滤液,减压蒸馏除去乙醇,浓缩,得浓缩液,备用;
S5、将白附子、陈皮、荞麦、凉山虫草、甘草的粗粉与S3的滤渣混匀,按照上述粗粉及滤渣总重量的7倍量加入蒸馏水,回流提取3小时,过滤,合并滤液,浓缩,得浓缩液,备用;
S6、将S2所得的青梅提取物与S4、S5所得的浓缩液合并,充分混合,以进风温度为110℃、出风温度为75℃进行离心喷雾干燥,制备成组合物;
S7、向S6所得的组合物中添加相应的辅料,利用现代通用制备技术,压片,制备成片剂。
实施例3:
本发明实施例3降尿酸保健品由以下重量份数的原料制备而成:青梅提取物30份、土茯苓20份、白附子16份、萆薢12份、陈皮18份、黄芪8份、荞麦16份、独活10份、凉山虫草10份、金钱草8份和甘草10份。
对比例1:
本发明对比例1所述降尿酸保健品由如下制备原料及其重量份数制备而成:青梅提取物24份、土茯苓15份、白附子11份、萆薢9份、陈皮14份、黄芪5份、荞麦12份、独活7份、凉山虫草7份、车前子5份和甘草7份。
制备方法参考实施例1。
对比例1与实施例1的区别在于,将金钱草替换为车前子。
对比例2:
本发明对比例2所述降尿酸保健品由如下制备原料及其重量份数制备而成:青梅提取物24份、土茯苓15份、白附子11份、萆薢9份、陈皮14份、黄芪5份、荞麦12份、独活7份、凉山虫草7份、金钱草5份和甘草7份。
对比例2与实施例1的区别在于,将实施例1制备方法步骤S2中的乙醇溶液回流提取料液比更改为1:30,其余步骤参考实施例1。
对比例3:
本发明对比例3所述降尿酸保健品由如下制备原料及其重量份数制备而成:青梅提取物24份、土茯苓15份、白附子11份、萆薢19份、陈皮14份、黄芪5份、荞麦12份、独活7份、凉山虫草7份、金钱草5份和甘草7份。
制备方法参考实施例1。
对比例3与实施例1的区别在于,增加了萆薢的重量份数。
试验例一、本发明的降大鼠血尿酸试验
1、试验对象:选取90只SPF级SD雄性大鼠,体重为225±25g,由暨南大学实验动物中心提供。
2、试验材料:本发明实施例1、实施例2、实施例3、对比例1、对比例2和对比例3制备的组合物片剂,加入2倍质量的水溶解;阳性对照药为别嘌醇片,购于广东彼迪药业有限公司,国药准字H44021368。
3、试验方法:将90只大鼠随机分为9组,分别为空白对照组、模型组、别嘌醇片组、实施例1-3组、对比例1-3组,每组各10只,各组的给药量如下:
空白对照组及模型组:灌胃等体积的生理盐水;
别嘌醇片组:别嘌醇片研磨成细粉,兑入蒸馏水中,灌胃给药,给药量相当于30g原药/Kg;
实施例1-3组:分别将实施例1-3组制备的片剂研磨成细粉,兑入蒸馏水中,灌胃给药,给药量相当于30g原药/Kg;
对比例1-3组:分别将对比例1-3组制备的片剂研磨成细粉,兑入蒸馏水中,灌胃给药,给药量相当于30g原药/Kg;
空白对照组和模型组灌胃给予等容量的0.5%CMC-Na溶液,其余各组动物按上述剂量分别灌胃给予相应量药物,空白对照组以生理盐水代替,1天给药1次,连续7d。末次给药30min后,空白对照组和各药物组进行高尿酸血症的造模,先灌胃给予剂量为100mg/kg次黄嘌呤,给药容量为1mL/100g,再皮下注射剂量为20mg/kg氧嗪酸钾盐,给药容量为0.5mL/100g。空白对照组同法操作给予等容量的0.5%CMC-Na溶液和等容量的生理盐水。造模后3h从大鼠眼眶静脉丛取血,3000r/min离心10min,分离血清,用尿酸测定试剂盒规定的检测方法测定血清尿酸值。
4、试验结果:
表1本发明保健品对大鼠血清尿酸值的影响
组别 | 数量(g) | 血清尿酸值(mol/L) |
空白对照组 | 10 | 89.77±12.45 |
模型组 | 10 | 191.25±12.37** |
别嘌醇片组 | 10 | 131.59±22.56## |
实施例1组 | 10 | 102.33±9.65##Δ |
实施例2组 | 10 | 101.45±11.52##Δ |
实施例3组 | 10 | 105.30±10.81##Δ |
对比例1组 | 10 | 123.45±7.28## |
对比例2组 | 10 | 127.52±12.54## |
对比例3组 | 10 | 118.25±8.92## |
与空白对照组比较,*P<0.05,**P<0.01;与模型组比较,#P<0.05,##P<0.01;与别嘌醇片组比较,ΔP<0.05,ΔΔP<0.01。
结果显示,模型组与空白对照组相比,血清尿酸值显著升高,具有统计学差异,说明造模成功。
与模型组比较,各个治疗组大鼠血清尿酸值增高均有降低作用,疗效显著(P<0.01或P<0.05)。值得注意的是,本发明实施例1-3组的疗效比阳性药组别嘌醇片的降血尿酸作用更加显著,具有统计学差异(P<0.05)。对比例1~3组保健品的药效与实施例1组比较均有所降低。
总体而言,本发明含有青梅提取物的组合物在降低人体尿酸方面的作用优于别嘌醇片组。但是,目前临床治疗显示,长期服用别嘌醇片会对人体的肝、肾造成严重的损伤,治疗中均存疗效不稳定、个体差异性大、治疗不彻底等缺陷。但是本发明组合物由纯天然中草药按照合适的配比制备而成,具有稳定性好、生物利用度高、毒副作用小的独特优势。
由于已经通过以上较佳实施例描述了本发明,在本发明的精神和/或范围内,任何针对本发明的替换/或组合来实施本发明,对于本领域的技术人员来说都是显而易见的,且包含在本发明之中。
Claims (10)
1.含有青梅提取物的组合物在制备降尿酸保健品中的用途,其特征在于,所述含有青梅提取物的组合物包括如下制备原料及其重量份数:
青梅提取物18-30份、土茯苓10-20份、白附子6-16份、萆薢6-12份、陈皮10-18份、黄芪2-8份、荞麦8-16份、独活4-10份、凉山虫草4-10份、金钱草2-8份和甘草4-10份。
2.如权利要求1所述的用途,其特征在于,所述含有青梅提取物的组合物包括如下制备原料及其重量份数:
青梅提取物24份、土茯苓15份、白附子11份、萆薢9份、陈皮14份、黄芪5份、荞麦12份、独活7份、凉山虫草7份、金钱草5份和甘草7份。
3.如权利要求1所述的用途,其特征在于,所述含有青梅提取物的组合物包括如下制备原料及其重量份数:
青梅提取物18份、土茯苓10份、白附子6份、萆薢6份、陈皮10份、黄芪2份、荞麦8份、独活4份、凉山虫草4份、金钱草2份和甘草4份。
4.如权利要求1所述的用途,其特征在于,所述含有青梅提取物的组合物包括如下制备原料及其重量份数:
青梅提取物30份、土茯苓20份、白附子16份、萆薢12份、陈皮18份、黄芪8份、荞麦16份、独活10份、凉山虫草10份、金钱草8份和甘草10份。
5.如权利要求1-4任一所述的用途,其特征在于,所述含有青梅提取物的组合物被制成片剂、胶囊剂、口服液或冲剂。
6.如权利要求1-4任一所述的用途,其特征在于,所述含有青梅提取物的组合物由以下步骤制得:
S1、采摘新鲜青梅,洗净后晾干,加入青梅重量1-2倍的蒸馏水,高速搅拌机研磨,过滤去杂质,得到青梅浆液;
S2、将S1制备的青梅浆液用70-80%的乙醇溶液回流提取1-3次,每次3-6h,合并提取液,静置,过滤去杂质,得青梅提取物,备用;
S3、称取其他各味原料,分别去杂质,洗净,烘干,切片后分别粉碎成粗粉;
S4、将土茯苓、萆薢、黄芪、独活和金钱草的粗粉混匀,按照上述粗粉总重量的6-12倍量加入体积浓度为70-95%的乙醇溶液,浸泡12-24h,回流提取2-4次,每次3-5h,过滤并保留滤渣,合并滤液,减压蒸馏除去乙醇,浓缩,得浓缩液,备用;
S5、将白附子、陈皮、荞麦、凉山虫草、甘草的粗粉与S3的滤渣混匀,按照上述粗粉及滤渣总重量的7-9倍量加入蒸馏水,回流提取3-6小时,过滤,合并滤液,浓缩,得浓缩液,备用;
S6、将S2所得的青梅提取物与S4、S5所得的浓缩液合并,充分混合,离心喷雾干燥,即得。
7.如权利要求6所述的用途,其特征在于,所述步骤S1中高速搅拌机的研磨转速为500-1000rpm,研磨时间为10-25min。
8.如权利要求6所述的用途,其特征在于,所述步骤S2中提取料液比为1:1-25。
9.如权利要求8所述的用途,其特征在于,所述步骤S2中提取料液比为1:10。
10.如权利要求6所述的用途,其特征在于,所述步骤S6中离心喷雾干燥机的进风温度为110-140℃,出风温度为75-95℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610395708.0A CN105901736A (zh) | 2016-06-06 | 2016-06-06 | 含有青梅提取物的组合物在制备降尿酸保健品中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610395708.0A CN105901736A (zh) | 2016-06-06 | 2016-06-06 | 含有青梅提取物的组合物在制备降尿酸保健品中的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105901736A true CN105901736A (zh) | 2016-08-31 |
Family
ID=56750425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610395708.0A Pending CN105901736A (zh) | 2016-06-06 | 2016-06-06 | 含有青梅提取物的组合物在制备降尿酸保健品中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105901736A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112674327A (zh) * | 2020-12-24 | 2021-04-20 | 烟台新时代健康产业有限公司 | 一种具有降尿酸功能的保健食品 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101190280A (zh) * | 2006-11-27 | 2008-06-04 | 杭州尤美特科技有限公司 | 梅树非果部分提取物的用途 |
CN103099999A (zh) * | 2013-01-21 | 2013-05-15 | 孙新虎 | 一种治疗痛风病中药 |
CN104367899A (zh) * | 2014-10-20 | 2015-02-25 | 安徽省颍上县中医院 | 一种治疗高尿酸血症的中药组合物 |
CN105288371A (zh) * | 2015-11-30 | 2016-02-03 | 姜晓红 | 一种治疗痛风的中药组合物 |
-
2016
- 2016-06-06 CN CN201610395708.0A patent/CN105901736A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101190280A (zh) * | 2006-11-27 | 2008-06-04 | 杭州尤美特科技有限公司 | 梅树非果部分提取物的用途 |
CN103099999A (zh) * | 2013-01-21 | 2013-05-15 | 孙新虎 | 一种治疗痛风病中药 |
CN104367899A (zh) * | 2014-10-20 | 2015-02-25 | 安徽省颍上县中医院 | 一种治疗高尿酸血症的中药组合物 |
CN105288371A (zh) * | 2015-11-30 | 2016-02-03 | 姜晓红 | 一种治疗痛风的中药组合物 |
Non-Patent Citations (1)
Title |
---|
王进昆: "《这样吃,我的白发变黑发,年轻15岁!:台湾营养学博士王进昆的太极饮食法和太极食谱》", 30 September 2014 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112674327A (zh) * | 2020-12-24 | 2021-04-20 | 烟台新时代健康产业有限公司 | 一种具有降尿酸功能的保健食品 |
CN112674327B (zh) * | 2020-12-24 | 2023-01-24 | 烟台新时代健康产业有限公司 | 一种保健食品 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100518807C (zh) | 一种治疗肝硬化腹水的药物 | |
CN103099959B (zh) | 一种治疗溃疡性结肠炎的中药制剂及其制备方法 | |
CN102000299B (zh) | 一种治疗高脂血症的药物 | |
CN101695327B (zh) | 一种保健肾茶 | |
CN108096502B (zh) | 一种降尿酸代用茶及其制备方法 | |
CN101897925B (zh) | 一种治疗代谢综合症的药物组合物 | |
CN103230486B (zh) | 一种中药组合物及其制备方法以及在制备治疗脂肪肝药物中的应用 | |
CN107823357A (zh) | 一种绿色减肥贴剂及其制备方法 | |
CN104547961B (zh) | 一种治疗胆结石的中药组合物 | |
CN102293928A (zh) | 治疗高尿酸血症及痛风性关节炎的中药组合物及其制备方法与应用 | |
CN105901736A (zh) | 含有青梅提取物的组合物在制备降尿酸保健品中的用途 | |
CN103830337B (zh) | 一种治疗慢性酒精中毒性肝病的中药组合物 | |
CN103405574B (zh) | 一种治疗高血压的药物组合物 | |
CN106166262A (zh) | 一种治疗慢性肾衰竭的中药组合物 | |
CN104800729A (zh) | 益肾复元消白汤 | |
CN104524359B (zh) | 一种中药组合物、其制备方法及应用 | |
CN116870110B (zh) | 一种降尿酸药食同源组方及其制备方法与应用 | |
CN104206597B (zh) | 一种缓解肺肾阴虚症状的五味子保健茶及其制备方法 | |
CN101612275B (zh) | 治疗肾病综合症的中药及其制备方法 | |
CN105943860A (zh) | 一种用于治疗糖尿病的药物制剂及其制备方法 | |
CN105362999A (zh) | 一种防治小儿反复感冒的中药制剂及其制备方法 | |
CN101002889A (zh) | 一种治疗口苦型高血压的内服中药 | |
CN102961680B (zh) | 一种治疗胆结石、胆囊炎的中药制剂及其制备方法 | |
CN1194722C (zh) | 治疗肝炎的舒肝止痛膏 | |
CN104367862A (zh) | 一种治疗尿道结石的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160831 |
|
RJ01 | Rejection of invention patent application after publication |